The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View aml content recommended for you
Phase III LACEWING trial of gilteritinib in combination with azacitidine fails to meet its primary endpoint
On December 21, 2020, it was announced that the phase III LACEWING trial (NCT02752035) failed to meet its primary endpoint of a statistically significant improvement in overall survival with gilteritinib plus azacitidine, versus azacitidine alone, in patients with newly diagnosed, FLT3-mutated acute myeloid leukemia (AML), who were ineligible for intensive induction chemotherapy.1
Based on the results of this planned interim analysis, an independent data monitoring committee recommended terminating the study. Therefore, enrolment to the trial has ceased. A thorough review of the data has commenced, with results to be published in due course.1
Gilteritinib1
- A potent oral inhibitor of FMS-like tyrosine kinase 3 (FLT3) with demonstrated activity against FLT3-internal tandem duplication and FLT3-tyrosine kinase domain mutations.
- Previously approved by the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) for the treatment of patients with relapsed/refractory FLT3-mutated AML.
LACEWING trial (NCT02752035)1,2
- Randomized, open-label, multicenter trial of gilteritinib in combination with azacitidine in patients with newly diagnosed FLT3-mutated AML, who are ineligible for intensive induction chemotherapy.
- 250 adult patients randomized 2:1 to receive gilteritinib in combination with azacitidine or azacitidine alone.
- Dosage: Gilteritinib orally, daily (Day 1–28); azacitidine intravenous infusion or subcutaneous injection, daily for 7 days (Day 1–7); in 28-day cycles.
- Start date: August 1, 2016.
- Primary end point: Overall survival.
- Key secondary endpoints: Event-free survival, best response, complete remission (CR), composite CR, and CR with partial hematologic recovery.
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content